Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03926624 · ClinicalTrials.gov registry record · Phase 3
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
A Phase 3 study, sponsored by Delta-Fly Pharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 167
- Enrollment target
NCT03926624 is a Phase 3 study that was terminated before completion, run by Delta-Fly Pharma. The registered enrollment target is 167 participants.
The verdict
NCT03926624, a Phase 3 study, was terminated before completion, sponsored by Delta-Fly Pharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 167 participants
- Enrollment target
Study Summary
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), depending on the patient's prior induction treatment.
Interventions
- DRUG Azacitidine
- DRUG Decitabine
- DRUG DFP-10917
- DRUG Cytarabine
- DRUG Mitoxantrone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2019-11-22 |
| Est. Completion | 2026-01-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03926624
The ClinicalTrials.gov registry entry for NCT03926624 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Delta-Fly Pharma, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Azacitidine is the first listed.
NCT03926624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03926624 about?
NCT03926624 is a clinical study titled "Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage". Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-d...
What is the current status of trial NCT03926624?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 167 participants. The study started on 2019-11-22. Estimated completion is 2026-01-07.
What interventions are being tested in trial NCT03926624?
The interventions under investigation include: Azacitidine (DRUG), Decitabine (DRUG), DFP-10917 (DRUG), Cytarabine (DRUG), Mitoxantrone (DRUG).
Who is sponsoring clinical trial NCT03926624?
This trial is sponsored by Delta-Fly Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.